Regenix hits sales landmark for wound treatment
The product is primarily aimed at the treatment of hard to heal wounds, a common side effect of diabetes.
Around 10 per cent of Americans suffer from Type 1 or Type 2 diabetes and the disease is becoming increasingly prevalent.
Obesity is believed to account for 80 to 85 per cent of the risk of developing Type 2 diabetes and recent research suggests that obese people are up to 80 times more likely to develop it.
DermaPure is also used to treat conditions such as pressure ulcers and frostbite and the group is looking at other areas to expand in to.
Greg Bila, president of Tissue Regenix Woundcare, said: “Since launch in 2014, the uptake of DermaPure within a competitive marketplace has been highly encouraging and we are thrilled to announce the first $1m of sales.”
DermaPure tells the patient’s body to redirect the patient’s own cells to the wounded area, allowing the body to regenerate healthy tissue.
York-based Tissue Regenix said DermaPure is now available to 65 per cent of US insurance programme Medicare beneficiaries, spanning 31 states.
Gaining Medicare approval for DermaPure across America is a key element of Tissue Regenix’s strategy for full commercialisation of the product.
It allows the company to access the largest potential group of US patients who would be unable to get access to Tissue Regenix products without Medicare.
The US Medicare programme is a national social insurance programme which provides health insurance for citizens aged 65 and over. It is administered by bodies such as Noridian Healthcare Solutions and Palmetto GBA.